Who are LoDAC's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Consolidation, III HiDAraC cycle, II Consolidation HiDAraC.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lodac.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

LoDAC — Competitive Intelligence Brief

LoDAC (LoDAC) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside analog / Antimetabolite. Area: Oncology.

phase 3 Nucleoside analog / Antimetabolite DNA synthesis (cytidine deaminase inhibition pathway) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

LoDAC (LoDAC) — Sunshine Lake Pharma Co., Ltd.. LoDAC is a low-dose cytarabine formulation designed to improve tolerability and efficacy in hematologic malignancies.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
LoDAC TARGET	LoDAC	Sunshine Lake Pharma Co., Ltd.	phase 3	Nucleoside analog / Antimetabolite	DNA synthesis (cytidine deaminase inhibition pathway)
Consolidation, III HiDAraC cycle	Consolidation, III HiDAraC cycle	dr hab. n. med. Agnieszka Wierzbowska	phase 3	Nucleoside analog / Antimetabolite chemotherapy	DNA/RNA synthesis (cytidine deaminase inhibition pathway)
II Consolidation HiDAraC	II Consolidation HiDAraC	dr hab. n. med. Agnieszka Wierzbowska	phase 3	Nucleoside analog / Antimetabolite chemotherapy	DNA synthesis (cytidine deaminase inhibition pathway)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside analog / Antimetabolite class)

Sunshine Lake Pharma Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). LoDAC — Competitive Intelligence Brief. https://druglandscape.com/ci/lodac. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab